Eduard Gorina

5.5k total citations · 1 hit paper
39 papers, 3.8k citations indexed

About

Eduard Gorina is a scholar working on Pulmonary and Respiratory Medicine, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Eduard Gorina has authored 39 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 16 papers in Hematology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Eduard Gorina's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (17 papers), Hemophilia Treatment and Research (16 papers) and Platelet Disorders and Treatments (9 papers). Eduard Gorina is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (17 papers), Hemophilia Treatment and Research (16 papers) and Platelet Disorders and Treatments (9 papers). Eduard Gorina collaborates with scholars based in United States, Germany and Italy. Eduard Gorina's co-authors include David J. Lederer, Elizabeth A. Fagan, Steven D. Nathan, Lisa Lancaster, Marilyn K. Glassberg, Ian Glaspole, David Kardatzke, Steven A. Sahn, Paul W. Noble and Jeffrey J. Swigris and has published in prestigious journals such as New England Journal of Medicine, Blood and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Eduard Gorina

38 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

2014 2.6k citations Elizabeth A. Fagan, Marilyn K. Glassberg et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eduard Gorina United States	18	2.9k	892	567	433	401	39	3.8k
E Pettersson Sweden	23	1.2k 0.4×	416 0.5×	243 0.4×	291 0.7×	149 0.4×	57	2.7k
Pieter van Paassen Netherlands	37	3.1k 1.1×	942 1.1×	196 0.3×	227 0.5×	400 1.0×	113	4.8k
Gülen Hatemi Türkiye	31	1.7k 0.6×	155 0.2×	482 0.9×	349 0.8×	141 0.4×	189	4.1k
Vicente Rodríguez‐Valverde Spain	26	1.2k 0.4×	185 0.2×	522 0.9×	375 0.9×	365 0.9×	67	3.2k
Leif Bostad Norway	24	821 0.3×	662 0.7×	58 0.1×	329 0.8×	270 0.7×	87	2.5k
Shigeko Inokuma Japan	24	564 0.2×	337 0.4×	429 0.8×	708 1.6×	276 0.7×	78	2.4k
Xinping Tian China	27	699 0.2×	159 0.2×	398 0.7×	263 0.6×	350 0.9×	214	2.8k
Alvise Berti Italy	27	1.1k 0.4×	844 0.9×	111 0.2×	227 0.5×	134 0.3×	114	2.6k
Fleur Cohen‐Aubart France	30	574 0.2×	1.9k 2.2×	140 0.2×	283 0.7×	477 1.2×	117	3.1k
Silvia Laura Bosello Italy	27	585 0.2×	218 0.2×	207 0.4×	436 1.0×	1.0k 2.6×	97	2.3k

Countries citing papers authored by Eduard Gorina

Since Specialization

Citations

This map shows the geographic impact of Eduard Gorina's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eduard Gorina with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eduard Gorina more than expected).

Fields of papers citing papers by Eduard Gorina

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eduard Gorina. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eduard Gorina. The network helps show where Eduard Gorina may publish in the future.

Co-authorship network of co-authors of Eduard Gorina

This figure shows the co-authorship network connecting the top 25 collaborators of Eduard Gorina. A scholar is included among the top collaborators of Eduard Gorina based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eduard Gorina. Eduard Gorina is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moan, Natacha Le, et al.. (2023). Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients. Advances in Therapy. 40(9). 3739–3750.

Gorina, Eduard, Martin Decaris, Scott Turner, et al.. (2020). PLN-74809, A Dual α _V β ₆ /α _V β ₁ , Oral, Selective Integrin Inhibitor, Is Well Tolerated and Reduces Lung TGF-β Activity in Healthy Volunteers. A4554–A4554. 2 indexed citations

Kaner, Robert J., Ednan K. Bajwa, Moustapha El-Amine, et al.. (2019). Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies. American Journal of Respiratory and Critical Care Medicine. 200(2). 133–139. 7 indexed citations

Richeldi, Luca, Evans R. Fernández Pérez, Ulrich Costabel, et al.. (2019). Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet Respiratory Medicine. 8(1). 25–33. 215 indexed citations

Holsbeke, Cedric Van, Stephen Porter, Eduard Gorina, et al.. (2018). Quantitative CT analysis using functional imaging is superior in describing disease progression in idiopathic pulmonary fibrosis compared to forced vital capacity. Respiratory Research. 19(1). 213–213. 31 indexed citations

Gorina, Eduard, Jeff Swigris, Peter LaCamera, et al.. (2018). Effect of pamrevlumab on the UCSD-SOBQ (University of California San Diego–Shortness of Breath Questionnaire) in patients with Idiopathic Pulmonary Fibrosis (IPF). PA5239–PA5239. 2 indexed citations

Khanna, Dinesh, Carlo Albera, Aryeh Fischer, et al.. (2016). An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. The Journal of Rheumatology. 43(9). 1672–1679. 192 indexed citations

Albera, Carlo, Ulrich Costabel, Elizabeth A. Fagan, et al.. (2016). Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. European Respiratory Journal. 48(3). 843–851. 113 indexed citations

Khanna, Dinesh, Carlo Albera, Aryeh Fischer, et al.. (2015). Safety and tolerability of pirfenidone (PFD) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)–The LOTUSS study. OA4489–OA4489. 2 indexed citations

10.

Rentz, Anne M., Emuella Flood, Regina B. Butler, et al.. (2009). Psychometric evaluation of a patient‐reported symptom assessment tool for adults with haemophilia (the HAEMO‐SYM). Haemophilia. 15(5). 1039–1047. 5 indexed citations

11.

Rentz, Anne M., Emuella Flood, Carmen Altisent, et al.. (2008). Cross‐cultural development and psychometric evaluation of a patient‐reported health‐related quality of life questionnaire for adults with haemophilia. Haemophilia. 14(5). 1023–1034. 71 indexed citations

12.

Powell, Jerry S., Diane J. Nugent, Jillian Harrison, et al.. (2008). Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. Journal of Thrombosis and Haemostasis. 6(2). 277–283. 45 indexed citations

13.

Santagostino, Elena, A. Faradji, Alfonso Iorio, et al.. (2007). Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: Experience in the standard clinical setting. Thrombosis and Haemostasis. 99(1). 52–58. 35 indexed citations

14.

Gill, Joan Cox, Chantal Rothschild, Marilyn J. Manco‐Johnson, et al.. (2005). Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A. Thrombosis and Haemostasis. 93(3). 457–467. 79 indexed citations

15.

Szende, Ágota, W. Schramm, Emuella Flood, et al.. (2003). Health‐related quality of life assessment in adult haemophilia patients: a systematic review and evaluation of instruments. Haemophilia. 9(6). 678–687. 43 indexed citations

16.

Tusell, J, José A. Aznar, Felipe Querol, et al.. (2002). Results of an orthopaedic survey in young patients with severe haemophilia in Spain. Haemophilia. 8(s2). 38–42. 35 indexed citations

17.

Cordón, F., et al.. (2002). Single-dose ciprofloxacin versus 3 days of norfloxacin in uncomplicated urinary tract infections in women. Clinical Microbiology and Infection. 8(1). 50–54. 20 indexed citations

18.

Aznar, José A., M Magallón, Felipe Querol, Eduard Gorina, & J Tusell. (2000). The orthopaedic status of severe haemophiliacs in Spain. Haemophilia. 6(3). 170–176. 101 indexed citations

19.

Scharrer, I., H.‐H. Brackmann, Sultan Y, et al.. (2000). Efficacy of a sucrose‐formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A. Haemophilia. 6(6). 614–618. 23 indexed citations

20.

Ramis, Joaquim, et al.. (1991). Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose. European Journal of Drug Metabolism and Pharmacokinetics. 16(4). 269–273. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact